JP2019526628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526628A5 JP2019526628A5 JP2019531594A JP2019531594A JP2019526628A5 JP 2019526628 A5 JP2019526628 A5 JP 2019526628A5 JP 2019531594 A JP2019531594 A JP 2019531594A JP 2019531594 A JP2019531594 A JP 2019531594A JP 2019526628 A5 JP2019526628 A5 JP 2019526628A5
- Authority
- JP
- Japan
- Prior art keywords
- msoh
- compound
- suitable solvent
- crystal form
- isolating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 239000002904 solvent Substances 0.000 claims 17
- 239000013078 crystal Substances 0.000 claims 16
- 239000000725 suspension Substances 0.000 claims 9
- 238000001035 drying Methods 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022113230A JP2022137223A (ja) | 2016-08-31 | 2022-07-14 | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382153P | 2016-08-31 | 2016-08-31 | |
| US62/382,153 | 2016-08-31 | ||
| PCT/US2017/049400 WO2018045043A1 (en) | 2016-08-31 | 2017-08-30 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113230A Division JP2022137223A (ja) | 2016-08-31 | 2022-07-14 | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526628A JP2019526628A (ja) | 2019-09-19 |
| JP2019526628A5 true JP2019526628A5 (enExample) | 2020-10-08 |
Family
ID=61241572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531594A Pending JP2019526628A (ja) | 2016-08-31 | 2017-08-30 | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス |
| JP2022113230A Pending JP2022137223A (ja) | 2016-08-31 | 2022-07-14 | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113230A Pending JP2022137223A (ja) | 2016-08-31 | 2022-07-14 | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10301287B2 (enExample) |
| EP (1) | EP3506896A4 (enExample) |
| JP (2) | JP2019526628A (enExample) |
| KR (1) | KR20190057066A (enExample) |
| CN (1) | CN110167550A (enExample) |
| AU (1) | AU2017321594A1 (enExample) |
| BR (1) | BR112019003987A2 (enExample) |
| CA (1) | CA3034606A1 (enExample) |
| MX (1) | MX2019002057A (enExample) |
| RU (1) | RU2019109019A (enExample) |
| SG (1) | SG11201901438VA (enExample) |
| TW (1) | TW201823235A (enExample) |
| WO (1) | WO2018045043A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019238041A1 (zh) * | 2018-06-12 | 2019-12-19 | 南京明德新药研发有限公司 | 一种丙烯酰胺类化合物的晶型及其制备方法 |
| WO2019245517A1 (en) * | 2018-06-18 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11613670B2 (en) | 2018-06-18 | 2023-03-28 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11591486B2 (en) | 2018-06-19 | 2023-02-28 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| WO2019245589A1 (en) | 2018-06-19 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| WO2019245534A1 (en) * | 2018-06-19 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| KR20210053921A (ko) * | 2018-08-31 | 2021-05-12 | 에보니크 오퍼레이션즈 게엠베하 | 중합체 분말을 제조하는 방법 |
| WO2021133811A1 (en) | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| EP4159730A4 (en) | 2020-05-22 | 2024-05-01 | Medshine Discovery Inc. | PYRIDINE DERIVATIVE AND APPLICATION THEREOF |
| US20240124690A1 (en) * | 2021-02-22 | 2024-04-18 | Asahi Kasei Kabushiki Kaisha | Composition Containing Cellulose Nanofibers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265270A (ja) | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
| AU2808495A (en) | 1994-07-04 | 1996-01-25 | Takeda Chemical Industries Ltd. | Phosphonic acid compounds, their production and use |
| WO1999032100A2 (en) | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| EP1104416A2 (en) | 1998-08-20 | 2001-06-06 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use as anti-hiv agents |
| CA2384145A1 (en) | 1999-09-06 | 2001-03-15 | Takeda Chemical Industries, Ltd. | Process for the preparation of 2,3-dihydroazepine compounds |
| US7371772B2 (en) | 2001-08-08 | 2008-05-13 | Takeda Pharmaceutical Company Limited | Bicyclic compound, production and use thereof |
| JP2004123694A (ja) * | 2002-03-12 | 2004-04-22 | Takeda Chem Ind Ltd | 光学活性スルホキシド誘導体の製造法 |
| EP1728504B1 (en) | 2004-03-24 | 2013-07-31 | Takeda Pharmaceutical Company Limited | Emulsion stabilizer |
| JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| CA2818308A1 (en) | 2010-11-18 | 2012-05-24 | Yale University | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| AU2013257951A1 (en) | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
| KR20160013068A (ko) | 2013-05-15 | 2016-02-03 | 토비라 쎄라퓨틱스, 인크. | 세니크리비록 조성물 및 이들을 만들고 이용하는 방법 |
| CA2941411A1 (en) * | 2014-03-21 | 2015-09-24 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| WO2015187663A1 (en) * | 2014-06-02 | 2015-12-10 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
| SG11201704837VA (en) | 2014-12-23 | 2017-07-28 | Tobira Therapeutics Inc | Process of making cenicriviroc and related analogs |
-
2017
- 2017-08-30 JP JP2019531594A patent/JP2019526628A/ja active Pending
- 2017-08-30 CA CA3034606A patent/CA3034606A1/en not_active Abandoned
- 2017-08-30 KR KR1020197008786A patent/KR20190057066A/ko not_active Withdrawn
- 2017-08-30 EP EP17847477.1A patent/EP3506896A4/en not_active Withdrawn
- 2017-08-30 MX MX2019002057A patent/MX2019002057A/es unknown
- 2017-08-30 AU AU2017321594A patent/AU2017321594A1/en not_active Abandoned
- 2017-08-30 BR BR112019003987A patent/BR112019003987A2/pt not_active Application Discontinuation
- 2017-08-30 US US15/691,191 patent/US10301287B2/en active Active
- 2017-08-30 WO PCT/US2017/049400 patent/WO2018045043A1/en not_active Ceased
- 2017-08-30 CN CN201780061529.6A patent/CN110167550A/zh active Pending
- 2017-08-30 RU RU2019109019A patent/RU2019109019A/ru not_active Application Discontinuation
- 2017-08-30 SG SG11201901438VA patent/SG11201901438VA/en unknown
- 2017-08-30 TW TW106129555A patent/TW201823235A/zh unknown
-
2022
- 2022-07-14 JP JP2022113230A patent/JP2022137223A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521121A5 (enExample) | ||
| JP2016065086A5 (enExample) | ||
| JP2019509268A5 (enExample) | ||
| JP2017512186A5 (enExample) | ||
| RU2019109019A (ru) | Твердые формы ценикривирок мезилата и способы изготовления твердых форм ценикривирок мезилата | |
| JP2019505532A5 (enExample) | ||
| JP2018513863A5 (enExample) | ||
| JP2019516749A5 (enExample) | ||
| JP2010515682A5 (enExample) | ||
| JP2024095561A5 (enExample) | ||
| JP2016539136A5 (enExample) | ||
| CN105324375A (zh) | 盐酸尼洛替尼的多晶型形式 | |
| WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
| TWI780270B (zh) | 固體分散體 | |
| JP2018514507A5 (enExample) | ||
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| CN109311893A (zh) | 含有取代环戊基的吡咯并嘧啶化合物 | |
| JP6621761B2 (ja) | 薬学的に活性な化合物の固体形態 | |
| CN106866483A (zh) | 布瓦西坦的晶型c及其制备方法 | |
| JP2018516946A5 (enExample) | ||
| JP2007519747A5 (enExample) | ||
| JP2020500907A5 (enExample) | ||
| CN107427495A (zh) | 包含雷迪帕韦和索非布韦的药物组合物 | |
| US20190300483A1 (en) | POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT | |
| CN1303065C (zh) | 氨溴索半胱氨酸类似物盐及其制备方法和用途 |